f1

F-1 is IC50s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively. F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways.

Schidigerasaponin F1 is a useful organic compound for research related to life sciences. The catalog number is T125155 and the CAS number is 266998-42-9.

Coreanoside F1 is a useful organic compound for research related to life sciences. The catalog number is T126048 and the CAS number is 132282-69-0.

GSK-F1 (PI4KA inhibitor-F1) is a novel potent PI4KA inhibitor.

F1-RIBOTAC is a ribonuclease-targeting chimera (RIBOTAC) that reduces QSOX1-amRNA expression through an RNase L-dependent mechanism. It is applicable in cancer research. (Pink: RNA ligand; Black: linker; Blue: RNase L ligand.)

Ginsenoside F1 (20(S)-Ginsenoside F1) is an enzymatically modified derivative of ginsenoside Rg1, showing competitive inhibition of the activity of CYP3A4 and a weaker inhibition of the activity of CYP2D6.

(3S)-GSK-F1 is a selective small molecule inhibitor of Type III Phosphatidylinositol 4‑Kinase Alpha (PI4KIIIα), pIC50=8.3.

Marstenacisside F1, a polyoxypregnanoside derivative of Tenacigenin B with anti-inflammatory properties, has been isolated from Marsdenia tenacissima. It suppresses lipopolysaccharide-induced nitric oxide (NO) production in RAW 264.7 cells.

F1, an anti-inflammatory peptide, incorporates the HIV-1 Tat protein transduction domain linked with a 15-amino acid sequence from residues 46-60 of the inhibitor of NF-κB kinase-interacting peptide (IKIP). It effectively blocks LPS-induced phosphorylation of IκB kinase α (IKKα) and IKKβ, along with the nuclear translocation of NF-κB (p65) in mouse peritoneal macrophages at 5 µM concentration. F1, administered at 5 mg/kg in vivo, significantly reduces IL-6, TNF-α, and IL-1β serum levels and enhances survival in a mouse sepsis model induced by LPS.

Kaji-ichigoside F1 shows antiinflammatory/antinociceptive action in acetic acid-induced writhing and hot plate testing and in a carrageenan-induced paw edema model in mice and rats. Kaji-ichigoside F1 exhibits in vivo hepatoprotective effects, it inhibite

Momordicoside F1 may have antiproliferative activities against MCF-7, WiDr, HEp-2, and Doay human tumor cell lines.

Niga-ichigoside F1(NI) has anti-inflammatory, gastroprotective ,antinociceptive, and cytotoxic effects.

Goshonoside F1 is a lipid metabolite of the semi-glutinous variety of rice and can be used as an indicator for breeding superior rice.

3-Acetyl-ginsenoside F1 is a useful organic compound for research related to life sciences and the catalog number is TN6448.

GLF16 HCl is a fluorophore-coupled Sudan Black B analog that allows rapid detection, isolation and real-time tracking of senescent cells by fluorescence microscopy and flow cytometry.

F13714 fumarate is a selective 5-HT1A receptor-biased agonist with antidepressant-like properties after a single dose in a mouse model of chronic mild stress.

TRIM24/BRPF1-IN-2 is a selective dual TRIM24/BRPF1 inhibitor with anticancer activity that inhibits proliferation, gene and protein expression, and colony formation of prostate cancer cells in a dose-dependent manner.

CSF1R-IN-7 is a highly selective CSF-1R inhibitor with good brain penetration for the treatment of a variety of diseases associated with microglia-mediated neuroinflammation, particularly Alzheimer's disease and other neurodegenerative disorders.CSF-1R is a type III receptor tyrosine kinase that is expressed predominantly on microglia (immune cells in the brain) and regulates the development, survival and function of microglia.

MuRF1-IN-1 is an inhibitor of muscle ring finger 1.

F1063-0967 is a Dual-specificity phosphatase 26 (DUSP26) inhibitor with an IC50 of 11.62 μM.

CSF1R-IN-1 is a CSF1R inhibitor with an IC50 of 0.5 nM.

GNF179 Metabolite, the derivative of GNF179—an optimized 8,8-dimethyl IP analog—demonstrates significant potency (4.8 nM against the multidrug-resistant W2 strain) alongside in vitro metabolic stability and in vivo oral bioavailability.

Kif15-IN-2 is a kinesin Kif15 inhibitor with potential anticancer activity and can be used in prostate cancer research.

CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).